Skip to main content
SpringerLink
Log in

Treating paediatric Crohn’s disease is challenging but new treatments hold promise

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Paediatric Crohn’s disease is associated with a high disease burden and greater requirement for immunosuppression compared with adult-onset disease. Although anti-tumour necrosis factor therapy can be effective, many patients experience drug failure. Newer biologic and small molecule drugs that have a narrower immunomodulating target have shown promising efficacy in Crohn’s disease, including some in paediatric patients. This article reviews the efficacy and safety of these drugs, as well as common clinical challenges encountered in treating paediatric patients with this condition.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mitchel EB, Rosh JR. Pediatric management of Crohn’s disease. Gastroenterol Clin North Am. 2022;51(2):401–24.

    Article  PubMed  Google Scholar 

  2. Gallagher J, Rosh JR, Sahn B. The future of advanced therapies for pediatric Crohn’s disease. Pediatr Drugs. 2023;25(6):621–33.

    Article  Google Scholar 

  3. Verburgt CM, Ghiboub M, Benninga MA, et al. Nutritional therapy strategies in pediatric Crohn’s disease. Nutrients. 2021;13(1):212.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Walters TD, Kim MO, Denson LA, et al. Increased effectiveness of early therapy with anti-tumor necrosis factor-alpha vs an immunomodulator in children with Crohn’s disease. Gastroenterology. 2014;146(2):383–91.

    Article  CAS  PubMed  Google Scholar 

  5. Aggeletopoulou I, Assimakopoulos SF, Konstantakis C, et al. Interleukin 12/interleukin 23 pathway: biological basis and therapeutic effect in patients with Crohn’s disease. World J Gastroenterol. 2018;24(36):4093–103.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Hyams JS, Dubinsky MC, Baldassano RN. Infliximab is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease. Gastroenterology. 2017;152(8):1901-14.e3.

    Article  PubMed  Google Scholar 

  7. AbbVie Inc. ADALIMUMAB injection, for subcutaneous use: US prescribing information. 2023. https://www.accessdata.fda.gov/. Accessed 07 Feb 2024.

  8. Dayan JR, Dolinger M, Benkov K, et al. Real world experience with ustekinumab in children and young adults at a tertiary care pediatric inflammatory bowel disease center. J Pediatr Gastroenterol Nutr. 2019;69(1):61–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Atia O, Shavit-Brunschwig Z, Mould DR, et al. Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study. Lancet Gastroenterol Hepatol. 2023;8(1):31–42.

    Article  PubMed  Google Scholar 

  10. Sandborn WJ, Rebuck R, Wang Y, et al. Five-year efficacy and safety of ustekinumab treatment in Crohn’s disease: the IM-UNITI trial. Clin Gastroenterol Hepatol. 2022;20(3):578-90.e4.

    Article  CAS  PubMed  Google Scholar 

  11. Hyams JS, Turner D, Cohen SA, et al. Pharmacokinetics, safety and efficacy of intravenous vedolizumab in paediatric patients with ulcerative colitis or Crohn’s disease: results from the phase 2 HUBBLE Study. J Crohns Colitis. 2022;16(8):1243–54.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Rosh JR, Turner D, Griffiths A, et al. Ustekinumab in paediatric patients with moderately to severely active Crohn’s disease: pharmacokinetics, safety, and efficacy results from UniStar, a phase 1 study. J Crohns Colitis. 2021;15(11):1931–42.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Lee SD, Singla A, Harper J, et al. Tofacitinib appears well tolerated and effective for the treatment of patients with refractory Crohn’s disease. Dig Dis Sci. 2022;67(8):4043–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Fenster M, Alayo QA, Khatiwada A, et al. Real-world effectiveness and safety of tofacitinib in Crohn’s disease and IBD-U: a multicenter study from the TROPIC consortium. Clin Gastroenterol Hepatol. 2021;19(10):2207-9.e3.

    Article  CAS  PubMed  Google Scholar 

  15. Panes J, Sandborn WJ, Schreiber S, et al. Tofacitinib for induction and maintenance therapy of Crohn’s disease: results of two phase IIb randomised placebo-controlled trials. Gut. 2017;66(6):1049–59.

    Article  CAS  PubMed  Google Scholar 

  16. Taylor NP. Roche lets go of etro, dumping phase 3 Crohn's prospect 18 months after posting weak colitis data. 2022. https://www.fiercebiotech.com/. Accessed 07 Feb 2024.

  17. Sandborn WJ, Panes J, Danese S, et al. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn’s disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2023;8(1):43–55.

    Article  PubMed  Google Scholar 

  18. Schwartz DA, Peyrin-Biroulet L, Lasch K, et al. Efficacy and safety of 2 vedolizumab intravenous regimens for perianal fistulizing Crohn’s disease: ENTERPRISE study. Clin Gastroenterol Hepatol. 2022;20(5):1059-67.e9.

    Article  CAS  PubMed  Google Scholar 

  19. Turner D, Rosh JR, Cohen SA, et al. Ustekinumab in paediatric patients with moderately to severely active Crohn’s disease: results from the UniStar study long-term extension [abstract no. P671]. J Crohns Colitis. 2023;17(Suppl 1):i802–3.

    Article  Google Scholar 

  20. Yerushalmy-Feler A, Pujol-Muncunill G, Martin-de-Carpi J, et al. Safety and potential efficacy of escalating dose of ustekinumab in pediatric Crohn disease (the Speed-up study): a multicenter study from the Pediatric IBD Porto Group of ESPGHAN. J Pediatr Gastroenterol Nutr. 2022;75(6):717–23.

    Article  CAS  PubMed  Google Scholar 

  21. Attauabi M, Burisch J, Seidelin JB. Efficacy of ustekinumab for active perianal fistulizing Crohn’s disease: a systematic review and meta-analysis of the current literature. Scand J Gastroenterol. 2021;56(1):53–8.

    Article  CAS  PubMed  Google Scholar 

  22. AbbVie Inc. SKYRIZI (risankizumab-rzaa) injection, for subcutaneous or intravenous use: US prescribing information. 2023. https://dailymed.nlm.nih.gov/. Accessed 07 Feb 2024.

  23. D’Haens G, Panaccione R, Baert F, et al. Risankizumab as induction therapy for Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399(10340):2015–30.

    Article  CAS  PubMed  Google Scholar 

  24. Ferrante M, Panaccione R, Baert F, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn’s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022;399(10340):2031–46.

    Article  CAS  PubMed  Google Scholar 

  25. Fumery M, Defrance A, Roblin X, et al. Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn’s disease: a GETAID multicentre cohort study. Aliment Pharmacol Ther. 2023;57(4):426–34.

    Article  CAS  PubMed  Google Scholar 

  26. Sandborn WJ, D’Haens GR, Reinisch W, et al. Guselkumab for the treatment of Crohn’s disease: induction results from the phase 2 GALAXI-1 study. Gastroenterology. 2022;162(6):1650-64.e8.

    Article  CAS  PubMed  Google Scholar 

  27. Sands BE, Peyrin-Biroulet L, Kierkus J, et al. Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with Crohn’s disease. Gastroenterology. 2022;162(2):495–508.

    Article  CAS  PubMed  Google Scholar 

  28. Collen LV. Rapid clinical remission with upadacitinib in a pediatric patient with refractory Crohn’s disease. Inflamm Bowel Dis. 2023;29(7):1175–6.

    Article  PubMed  Google Scholar 

  29. Loftus EV, Panes J, Lacerda AP, et al. Upadacitinib induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2023;388(21):1966–80.

    Article  CAS  PubMed  Google Scholar 

  30. D’Haens G, Panes J, Louis E, et al. Upadacitinib was efficacious and well-tolerated over 30 months in patients with Crohn’s disease in the CELEST extension study. Clin Gastroenterol Hepatol. 2022;20(10):2337-46.e3.

    Article  CAS  PubMed  Google Scholar 

  31. Sandborn WJ, Feagan BG, Loftus EV, et al. Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn’s disease. Gastroenterology. 2020;158(8):2123–38.e8.

    Article  CAS  PubMed  Google Scholar 

  32. Vermeire S, Schreiber S, Petryka R, et al. Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389(10066):266–75.

    Article  CAS  PubMed  Google Scholar 

  33. D’Haens GR, Lee S, Taylor SA, et al. Filgotinib for the treatment of small bowel Crohn’s disease: the DIVERGENCE 1 trial. Gastroenterology. 2023;165(1):289–92.e3.

    Article  CAS  PubMed  Google Scholar 

  34. Feagan BG, Sandborn WJ, Danese S, et al. Ozanimod induction therapy for patients with moderate to severe Crohn’s disease: a single-arm, phase 2, prospective observer-blinded endpoint study. Lancet Gastroenterol Hepatol. 2020;5(9):8119–828.

    Google Scholar 

  35. Ahmed W, Galati J, Kumar A, et al. Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022;20(3):e361–79.

    Article  CAS  PubMed  Google Scholar 

  36. Dolinger MT, Spencer EA, Lai J, et al. Dual biologic and small molecule therapy for the treatment of refractory pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2021;27:1210–4.

    Article  PubMed  Google Scholar 

  37. Wlazlo M, Meglicka M, Wiernicka A, et al. Dual biologic therapy in moderate to severe pediatric inflammatory bowel disease: a retrospective study. Children (Basel). 2022;10(1):11.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Lightner AL, Otero-Pineiro A, Reese J, et al. A phase I study of ex vivo expanded allogeneic bone marrow-derived mesenchymal stem cells for the treatment of pediatric perianal fistulizing Crohn’s disease. Inflamm Bowel Dis. 2023;29(12):1912–9.

    Article  PubMed  Google Scholar 

  39. Garcia-Olmo D, Gilaberte I, Binek M, et al. Follow-up study to evaluate the long-term safety and efficacy of darvadstrocel (mesenchymal stem cell treatment) in patients with perianal fistulizing Crohn’s disease: ADMIRE-CD phase 3 randomized controlled trial. Dis Colon Rectum. 2022;65(5):713–20.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Vieujean S, Loly JP, Boutaffala L, et al. Mesenchymal stem cell injection in Crohn’s disease strictures: a phase I-II clinical study. J Crohns Colitis. 2022;16(3):506–10.

    Article  PubMed  Google Scholar 

  41. Green MS, Purohi M, Sadacharam K, et al. Efficacy of hyperbaric oxygen in patients with Crohn’s disease: two case reports. Undersea Hyperb Med. 2013;40(2):201–4.

    PubMed  Google Scholar 

  42. Kante B, Sahu P, Kedia S, et al. Efficacy and tolerability of hyperbaric oxygen therapy in small bowel stricturing Crohn’s disease: a pilot study. Intest Res. 2022;20(2):231–9.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Lansdorp CA, Gecse KB, Buskens CJ, et al. Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn’s disease. Aliment Pharmacol Ther. 2021;53(5):587–97.

    Article  CAS  PubMed  Google Scholar 

  44. Lansdorp CA, Buskens CJ, Gecse KB, et al. Hyperbaric oxygen therapy for the treatment of rectovaginal fistulas in patients with Crohn’s disease: results of the HOT-REVA pilot study. BJS Open. 2021;5(3):zrab042.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Dulai PS, Gleeson MW, Taylor D, et al. Systematic review: the safety and efficacy of hyperbaric oxygen therapy for inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39(11):1266–75.

    Article  CAS  PubMed  Google Scholar 

  46. Lee D, Baldassano RN, Otley AR, et al. Comparative effectiveness of nutritional and biological therapy in North American children with active Crohn’s disease. Inflamm Bowel Dis. 2015;21(8):1786–93.

    Article  PubMed  Google Scholar 

  47. Chen JM, He LW, Yan T, et al. Oral exclusive enteral nutrition induces mucosal and transmural healing in patients with Crohn’s disease. Gastroenterol Rep (Oxf). 2019;7(3):176–84.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Levine A, Wine E, Assa A, et al. Crohn’s disease exclusion diet plus partial enteral nutrition induces sustained remission in a randomized controlled trial. Gastroenterology. 2019;157(2):440-50.e8.

    Article  PubMed  Google Scholar 

  49. Cohen SA, Gold BD, Oliva S, et al. Clinical and mucosal improvement with specific carbohydrate diet in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2014;59(4):516–21.

    Article  CAS  PubMed  Google Scholar 

  50. Suskind DL, Lee D, Kim YM, et al. The specific carbohydrate diet and diet modification as induction therapy for pediatric Crohn’s disease: a randomized diet controlled trial. Nutrients. 2020;12(12):3749.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Lewis JD, Sandler RS, Brotherton C, et al. A randomized trial comparing the specific carbohydrate diet to a Mediterranean diet in adults with Crohn’s disease. Gastroenterology. 2021;161(3):837-52.e9.

    Article  CAS  PubMed  Google Scholar 

  52. Svolos V, Hansen R, Nichols B, et al. Treatment of active Crohn’s disease with an ordinary food-based diet that replicates exclusive enteral nutrition. Gastroenterology. 2019;156(5):1354-67.e6.

    Article  PubMed  Google Scholar 

  53. Sinniger V, Pellissier S, Fauvelle F, et al. A 12-month pilot study outcomes of vagus nerve stimulation in Crohn’s disease. Neurogastroenterol Motil. 2020;32(10):e13911.

    Article  CAS  PubMed  Google Scholar 

  54. Sahn B, Pascuma K, Kohn N, et al. Transcutaneous auricular vagus nerve stimulation attenuates inflammatory bowel disease in children: a proof-of-concept clinical trial. Bioelectron Med. 2023;9(1):23.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand

    Tina Nie

Authors
  1. Tina Nie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tina Nie.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and conflict of interest

T. Nie is a salaried employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.

Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability

Not applicable.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nie, T. Treating paediatric Crohn’s disease is challenging but new treatments hold promise. Drugs Ther Perspect 40, 121–126 (2024). https://doi.org/10.1007/s40267-024-01056-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-024-01056-x

Search

Navigation